Login Get Started
Browse Breadcrumb chevron Shares Breadcrumb chevron Healthcare Breadcrumb chevron Pharmaceuticals Breadcrumb chevron Biotest AG
Biotest AG logo

BIO3 - Biotest AG Reuters News

€29.6 -0.2  -0.7%

Last Trade - 13/04/21

Sector
Healthcare
RiskRating
Conservative
Size
Mid Cap
Style
Style Neutral
Market Cap £1.02bn
Enterprise Value £1.35bn
Revenue £419.7m
Position in Universe 387th / 1046
Quality
Value
Momentum
StockRank™
StockReport™
Tools
Compare with... Run through checklist
Accounts
Balance sheet Income statement Cashflow statement Dividend summary
Charts News Discussions BIO3 Dividends
Reuters News
All News Reuters News Company Announcements
EUROPE RESEARCH ROUNDUP: Credit Suisse, Scor, SAP, Wacker Chemie
8th Jan '14 News
RESEARCH ALERT-Biotest: HSBC cuts to neutral
8th Jan '14 News
German stocks - Factors to watch on December 10
10th Dec '13 News
German stocks - Factors to watch on December 10
10th Dec '13 News
CORRECTED-Germany's Biotest under investigation over bribery allegations
5th Nov '13 News
Germany's Biotest under investigation over bribery allegations
4th Nov '13 News
German stocks - Factors to watch on September 9
9th Sep '13 News
EUROPE RESEARCH ROUNDUP: Carlsberg, Deutsche Bank, GlaxoSmithKline, ING
14th Aug '13 News
UPDATE 1-RLPC-Bain agrees 230 mln stg buyout of Plasma Resources UK
18th Jul '13 News
RLPC-Bain agrees 200 mln stg buyout of Plasma Resources UK -source
18th Jul '13 News
S.Korea's Green Cross considers buying UK's Plasma Resources
24th Apr '13 News
S.Korea's Green Cross considers buying UK's Plasma Resources
24th Apr '13 News
Germany's Biotest targets UK blood plasma peer PRUK
15th Mar '13 News
RPT-UPDATE 1-Basic hygiene at risk in debt-stricken Greek hospitals
5th Dec '12 News
UPDATE 1-Basic hygiene at risk in debt-stricken Greek hospitals
4th Dec '12 News
EU health officials fear for disease control in Greece
4th Dec '12 News
Drugmakers offer to cap Greece's medicines bill
4th Nov '12 News
© Stockopedia 2021, Refinitiv, Share Data Services.
Youtube Instagram RSS
This site cannot substitute for professional investment advice or independent factual verification. To use it, you must accept our Terms of Use, Privacy and Disclaimer policies.